Vanda Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VANDA PHARMS INC, and what generic alternatives to VANDA PHARMS INC drugs are available?
VANDA PHARMS INC has four approved drugs.
There are forty-six US patents protecting VANDA PHARMS INC drugs.
There are three hundred and seventy-five patent family members on VANDA PHARMS INC drugs in forty-three countries and twelve supplementary protection certificates in eleven countries.
Summary for Vanda Pharms Inc
| International Patents: | 375 |
| US Patents: | 46 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for Vanda Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 11,850,229 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 11,759,446 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Vanda Pharms Inc | PONVORY | ponesimod | TABLET;ORAL | 213498-002 | Mar 18, 2021 | RX | Yes | No | RE43728 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Vanda Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | PONVORY | ponesimod | TABLET;ORAL | 213498-006 | Mar 18, 2021 | RE43728 | ⤷ Subscribe |
| Vanda Pharms Inc | PONVORY | ponesimod | TABLET;ORAL | 213498-010 | Mar 18, 2021 | 9,000,018 | ⤷ Subscribe |
| Vanda Pharms Inc | PONVORY | ponesimod | TABLET;ORAL | 213498-002 | Mar 18, 2021 | 9,000,018 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VANDA PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2018-01-31 |
| ➤ Subscribe | Tablets | 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mg | ➤ Subscribe | 2013-05-06 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2018-01-31 |
International Patents for Vanda Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2673603 | ⤷ Subscribe |
| Colombia | 7131366 | ⤷ Subscribe |
| China | 111603460 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vanda Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3256125 | 2290019-5 | Sweden | ⤷ Subscribe | PRODUCT NAME: PONESIMOD AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT. REG. NO/DATE: EU/1/21/1550 20210521; FIRST REG.: GE EU/1/21/1550 20210521 |
| 3256125 | C03256125/01 | Switzerland | ⤷ Subscribe | PRODUCT NAME: PONESIMOD; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68114 16.11.2021 |
| 3256125 | 301174 | Netherlands | ⤷ Subscribe | PRODUCT NAME: PONESIMOD (IUPAC NAAM: (R)-5-(3-CHLOOR-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDEEN)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ON), DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/21/1550 20210521 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
